

CB21 6AD

Cambridgeshire

Suite 2, Riverside 3, Granta Park, Great Abington

Swedish Orphan Biovitrum Ltd

Materials developed and distributed by:

By reporting side effects you can help provide more information on the safety of medicines.

Google Play or Apple App Store.

Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the

You can also report side effects directly via:

any possible side effects not listed in the Package Leaflet.

If you/your child get any side effects, talk to your doctor, pharmacist or nurse. This includes

Reporting of side effects

TREATMENT WITH KINERET® (anakinra)

Patient's name:

Caregiver's name (for children):

Patient's dose:

Physician/doctor's name and phone number:

This patient reminder card should only be given
to patients that have been or are due to start
treatment with Kineret

Important safety information regarding Still's disease

Macrophage activation syndrome (MAS) is a serious complication of Still's disease. Left untreated MAS can be life threatening. The risk for developing MAS is increased if you have an infection or if your Still's disease symptoms are poorly controlled. Symptoms of MAS can be e.g. persistent high fever, swelling of lymph nodes, and persistent rash.

Kineret[®] (anakinra) can increase the risk for a serious infection. Symptoms might be persistent high fever, shivers, cough, headache, and redness and tenderness of the skin. Also, persistent low-grade fever, weight loss, and persistent cough can be signs of an infection.

If you develop signs of an infection or worsening of your Still's disease symptoms you should contact your health care provider as soon as possible.